NCT06955169 2026-04-16
MOMENTUM-1
RTOG Foundation, Inc.
Phase 2 Recruiting
Clinical Trials
23 trialsNCT05843253 2026-03-20
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Nationwide Children's Hospital
Phase 2 Recruiting
NCT06326190 2025-09-16
LUMEN-1
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Recruiting
NCT06126588 2025-03-11
ELUMEN
Central Hospital, Nancy, France
Phase 2 Recruiting
NCT01345136 2024-02-13
Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma
Jonsson Comprehensive Cancer Center
Phase 2 Terminated
NCT02332902 2023-12-20
DCLNF1
The University of Texas Health Science Center, Houston
Phase 2 Completed
NCT02333565 2023-05-25
CEVOREM
Assistance Publique Hopitaux De Marseille
Phase 2 Completed
NCT02023905 2022-12-29
Everolimus With and Without Temozolomide in Adult Low Grade Glioma
University of California, San Francisco
Phase 2 Terminated
NCT03352427 2022-10-05
Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT00805961 2021-12-08
RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00972335 2021-11-10
Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT00843531 2020-09-29
RAD001 and Erlotinib in Patients With Neuroendocrine Tumors
University of California, San Francisco
Phase 2 Terminated
NCT00823459 2020-07-28
Everolimus in Treating Patients With Recurrent Low-Grade Glioma
University of California, San Francisco
Phase 2 Completed
NCT01158651 2020-02-05
NFC-RAD001
University of Alabama at Birmingham
Phase 2 Completed
NCT03632317 2019-08-19
A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas
University of Michigan Rogel Cancer Center
Phase 2 Withdrawn
NCT01305941 2018-12-17
A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT00782626 2018-08-15
Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02233049 2018-07-23
BIOMEDE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Unknown
NCT01419639 2017-07-18
Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2
NYU Langone Health
Phase 2 Completed
NCT01490476 2017-05-23
AFINF2
Assistance Publique - Hôpitaux de Paris
Phase 2 Completed
NCT01365468 2016-05-12
Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1)
Novartis
Phase 2 Terminated
NCT01152827 2015-05-20
PheoCarcRAD001
Seoul National University Hospital
Phase 2 Completed
NCT00515086 2011-09-22
Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM)
Novartis
Phase 2 Terminated